Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2025 09:58 ET | Source: Spherix Global Insights

Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch

EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance...
September 05, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.
December 05, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...